Phase I study of ixabepilone in combination with capecitabine in Japanese patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Background: Trabectedin (Tr) is ...
Currently, only 10% of the drugs that enter Phase I receive marketing approval from the U.S. Food and Drug Administration (FDA), with unmanageable toxicity accounting for approximately 30% of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback